Scemblix
| Chemical Name | asciminib |
| Dosage Form | Film-coated tablets (oral; 20 mg, 40 mg |
| Drug Class | Kinase inhibitors |
| System | Blood |
| Company | Novartis |
| Approval Year | 2021 |
Indication
- For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors (TKIs)
- For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase with the T315I mutation